Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer

(2012) Nathan W. D. Lamond et al.   BREAST CANCER RESEARCH AND TREATMENT

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial

(2011) J. Huober et al.   BREAST

Survival and treatment patterns in elderly patients with advanced non-small-cell lung cancer in Manitoba

(2011) C. L. Baunemann Ott et al.   Current Oncology

Economic evaluation of the 21-gene signature (Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)

(2010) Masahide Kondo et al.   BREAST CANCER RESEARCH AND TREATMENT

Radiation treatment waiting times for breast cancer patients in Manitoba, 2001 and 2005

(2010) A.L. Cooke et al.   Current Oncology

Health economics in drug development: Efficient research to inform healthcare funding decisions

(2010) Peter S. Hall et al.   EUROPEAN JOURNAL OF CANCER

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

(2010) Eleftherios P. Mamounas et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection

(2010) Shelly S. Lo et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer

(2010) Miguel Martín et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer

(2010) D. T. Tsoi et al.   ONCOLOGIST

Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization

(2010) Shmuel H. Klang et al.   VALUE IN HEALTH

How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma

(2010) Isabelle Chabot et al.   VALUE IN HEALTH

Comparison of Treatment Received Versus Long-Standing Guidelines for Stage III Colon and Stage II/III Rectal Cancer Patients Diagnosed in Alberta, Saskatchewan, and Manitoba in 2004

(2009) Marilyn Cree et al.   Clinical Colorectal Cancer

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

(2008) Juhi Asad et al.   AMERICAN JOURNAL OF SURGERY

Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada

(2008) Noemi Muszbek et al.   CURRENT MEDICAL RESEARCH AND OPINION

Trial Assessing Individualized Options for Treatment for breast cancer: the TAILORx trial

(2008) Jo Anne Zujewski et al.   Future Oncology

Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis

(2008) Sorrel E. Wolowacz et al.   JOURNAL OF CLINICAL ONCOLOGY

Histopathologic variables predict Oncotype DX™ Recurrence Score

(2008) Melina B Flanagan et al.   MODERN PATHOLOGY

The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond

(2008) Angela Rocchi et al.   VALUE IN HEALTH